Literature DB >> 27255582

Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment.

Harrys A Torres1, Jean-Nicolas Vauthey2, Minas Platon Economides3, Parag Mahale3, Ahmed Kaseb4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27255582     DOI： 10.1016/j.jhep.2016.05.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  20 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

2.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

3.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

4.  Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C.

Authors:  Samuel O Antwi; Holly K Van Houten; Lindsey R Sangaralingham; Tushar Patel
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-26

Review 5.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 6.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

7.  Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Authors:  Kenji Ikeda; Yusuke Kawamura; Masahiro Kobayashi; Yoko Kominami; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

8.  Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.

Authors:  Annsa C Huang; Neil Mehta; Jennifer L Dodge; Francis Y Yao; Norah A Terrault
Journal:  Hepatology       Date:  2018-05-16       Impact factor: 17.425

9.  Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Sonal Singh; Amit Nautiyal; Yoon K Loke
Journal:  Frontline Gastroenterol       Date:  2018-07-30

10.  Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents.

Authors:  Gang Ning; Yi-Ting Li; You-Ming Chen; Ying Zhang; Ying-Fu Zeng; Chao-Shuang Lin
Journal:  Can J Gastroenterol Hepatol       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.